Biovitrum and Swedish Orphan will be combined forming Swedish Orphan Biovitrum with pro forma revenues 2009 of approximately SEK 2 billion and an EBITDA margin of 15 percent. Biovitrum will pay an upfront consideration of SEK 3.5 billion (on a cash and debt free basis), to be financed by a fully guaranteed rights issue, an issue in kind and bank financing.

Contact
If you, as a shareholder, have any questions - please contact Investor Relations at

Indicative timetable

Date	Event	Status
Nov 6	Notice to EGM in Biovitrum	OK
Nov 20	Information material to the EGM held available at www.biovitrum.com	link to material
Dec 2	Announcement of subscription price and offer ratio of the Rights Issue	OK
Dec 4	EGM	OK
Dec 7	First day of trading in the shares, excluding right to participate in the Rights Issue	OK
Dec 9	Prospectus made public	link to material
Dec 9	Record date for participation in the Rights Issue, i.e. shareholders registered in the share register of Biovitrum as of this day will receive subscription rights for participation in the Rights Issue
Dec 11-23	Trading in subscription rights
Dec 23	Prospectus Supplement	link to material
Dec 11-30	Subscription period	OK
Jan 8	Announcement of results in the Rights Issue	OK
Jan 14	Estimated closing of the Transaction	OK